Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple “sequential” or “concomitant” treatment to eradicateH. pyloriinfection

Su1696 Efficacy of Second-Line Treatment for Helicobacter pylori Infection: Moxifloxacin-Containing Triple Therapy vs. Bismuth-Containing Quadruple Therapy

(2015) Kwang Hyun Chung et al.   GASTROENTEROLOGY

Management ofHelicobacter pyloriinfection—the Maastricht IV/ Florence Consensus Report

(2012) Peter Malfertheiner et al.   GUT

Helicobacter pyloriresistance to antibiotics in Europe and its relationship to antibiotic consumption

(2012) Francis Megraud et al.   GUT

Helicobacter pylori Infection: Sequential Therapy Followed by Levofloxacin-Containing Triple Therapy provides a Good Cumulative Eradication Rate

(2012) Marco Manfredi et al.   HELICOBACTER

Guide Regarding Choice of Second-line Therapy to Obtain a High Cumulative Cure Rate

(2012) David Y. Graham et al.   HELICOBACTER

A modified Bismuth-Containing Quadruple Therapy Including a Short Course of Furazolidone for Helicobacter pylori Eradication After Sequential Therapy Failure

(2012) Hafez Fakheri et al.   HELICOBACTER

Second-line Therapy With Levofloxacin After Failure of Treatment to Eradicate Helicobacter pylori Infection

(2012) Javier P. Gisbert et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Rescue Therapy forHelicobacter pyloriInfection 2012

(2012) Javier P. Gisbert   Gastroenterology Research and Practice

Furazolidone inHelicobacter pyloritherapy: Misunderstood and often unfairly maligned drug told in a story of French bread

(2012) DavidY Graham et al.   Saudi Journal of Gastroenterology

Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori

(2011) J. P. Gisbert et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice

(2010) Stefano Pontone et al.   DIGESTIVE AND LIVER DISEASE

Sequential or Concomitant Therapy for Helicobacter pylori Eradication?

(2010) Angelo Zullo et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

In Response:

(2010) Javier P. Gisbert   JOURNAL OF CLINICAL GASTROENTEROLOGY

Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis

(2010) Yuqin Li et al.   WIENER KLINISCHE WOCHENSCHRIFT

Furazolidone therapy for Helicobacter pylori: Is it effective and safe?

(2009) Vincenzo De Francesco et al.   WORLD JOURNAL OF GASTROENTEROLOGY